|Articles|April 1, 2020
- Pharmaceutical Executive-04-01-2020
- Volume 40
- Issue 4
Pharmaceutical Executive, April 2020 Issue (PDF)
Click the title above to open the Pharmaceutical Executive April 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 5 years ago
HBA's Woman of the Year 2020: A Motivated Missionover 5 years ago
Doubling Down on D&Iover 5 years ago
COVID-19 Ripple Effects for Pharmaover 5 years ago
Prescribing Patterns: How to Get Ahead of the Trendsover 5 years ago
There’s No Easing the Price-vs.-Value Debateover 5 years ago
Payer Perspectives on Gene Therapy Reimbursementover 5 years ago
Covid-19 Pandemic Thrusts Biopharma R&D to Forefrontover 5 years ago
Transforming the CIO Role to Embrace Digital Healthover 5 years ago
Country Report: The Czech RepublicNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
2
Merck Planning $70 Billion Investment for US Expansion
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
